<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362010</url>
  </required_header>
  <id_info>
    <org_study_id>FX2010-03</org_study_id>
    <nct_id>NCT01362010</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients</brief_title>
  <official_title>Pilot, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Acne Vulgaris Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyne Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vyne Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and safety and to determine whether&#xD;
      FXFM244 Antibiotic Foam is effective in the treatment of Acne Vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IIa prospective, multicenter, randomized, double blind, placebo controlled,&#xD;
      parallel group, dose range finding clinical study to evaluate the safety, tolerability and&#xD;
      efficacy of Minocycline Foam 1% and 4% for the treatment of Acne Vulgaris.&#xD;
&#xD;
      The study consists of a screening / baseline visit, a treatment period where patients will be&#xD;
      treated topically on the facial skin areas affected by acne twice daily for 12 weeks,&#xD;
      followed by a post-treatment follow up visit 4 weeks after end of treatment. The first dose&#xD;
      will be applied in the presence of the study investigator or his assignee. Subsequent&#xD;
      applications will be made by the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in lesions count</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change in lesion count (inflammatory, non-inflammatory, and total) after 12 weeks of treatment compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator global assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physician's Global Improvement Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change in lesions count</measure>
    <time_frame>12 weeks</time_frame>
    <description>The % change in lesions count (inflammatory, non-inflammatory, and total) after 12 weeks of treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of improvement by photographs</measure>
    <time_frame>12 weeks</time_frame>
    <description>The photographs will assist in comparison of efficacy at subsequent visits compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-reported outcome assessment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>safety parameters will be assessed by&#xD;
Physical examination&#xD;
Vital signs (HR, BP, Body temperature)&#xD;
Adverse events recording&#xD;
Clinical assessment of skin irritation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo foam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Active ingredient: None Route: Topical Dosage schedule: Once daily, evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Minocycline Foam FXFM244</intervention_name>
    <description>Topically applied once a day.</description>
    <arm_group_label>Placebo foam</arm_group_label>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 1%</arm_group_label>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 4%</arm_group_label>
    <other_name>FXFM244 antibiotic foam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of Acne Vulgaris with facial involvement.&#xD;
&#xD;
          -  A minimum of 20 but not more than 50 inflammatory lesions on the face (papules and/ or&#xD;
             pustules).&#xD;
&#xD;
          -  A minimum of 25 but not more than 100 non-inflammatory lesions on the face (opened&#xD;
             and/or closed comedones).&#xD;
&#xD;
          -  No significant nodulocystic acne on the face (≤ 2 lesions).&#xD;
&#xD;
          -  A score of &gt;3 (Moderate) on the Investigator's Global Assessment Scale.&#xD;
&#xD;
          -  Patient is male or female between the ages of 12 to 25.&#xD;
&#xD;
          -  No known medical conditions that, in the Investigator's opinion could interfere with&#xD;
             study participation.&#xD;
&#xD;
          -  Patient is willing to refrain from use of all other topical acne medications or&#xD;
             antibiotics during the study.&#xD;
&#xD;
          -  Patient is willing to refrain from use of moisturizers, new brands of make-up, creams,&#xD;
             lotions, powders or any topical product other than the assigned treatment to the&#xD;
             treatment area.&#xD;
&#xD;
          -  Patient is willing and able to comply with all requirement of the protocol.&#xD;
&#xD;
          -  Patient is willing and able to give written informed consent prior to participation in&#xD;
             the study.&#xD;
&#xD;
          -  If female of childbearing potential, willing to use an acceptable form of birth&#xD;
             control during the study. Use of oral contraceptives must remain constant within 3&#xD;
             month prior to baseline and throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acne Conglobata, Acne Fulminas, secondary acne (chloracne, drug induced acne), or&#xD;
             severe acne requiring systemic treatment.&#xD;
&#xD;
          -  Presence of any facial skin condition that would interfere with the diagnosis or&#xD;
             assessment of Acne Vulgaris (e.g. rosacea, dermatitis, psoriasis, squamos cell&#xD;
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid&#xD;
             folliculitis, or bacterial folliculitis).&#xD;
&#xD;
          -  Excessive facial hair (beards, sideburns, moustaches, etc.) that would interfere with&#xD;
             diagnosis or assessment of Acne Vulgaris.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to Minocycline or any of the excipients in the&#xD;
             Study Medication.&#xD;
&#xD;
          -  Concomitant medication:&#xD;
&#xD;
          -  Use within 6 month prior to baseline of topical retinoids, oral retinoids (Accutane®)&#xD;
             or therapeutic Protocol No. FX2010-03 Foamix Ltd. Page 8 of 28 Confidential Ver: 02&#xD;
             Oct-31-2011 vitamin A supplements of greater than 10,000 units/day (multivitamins are&#xD;
             allowed).&#xD;
&#xD;
          -  Use of systemic steroids, systemic antibiotics, systemic treatment for Acne Vulgaris,&#xD;
             systemic antiinflammatory agents within 4 weeks prior to baseline.&#xD;
&#xD;
          -  Use of topical steroids, α-hydroxy/glycolic acid, benzoyl peroxide, topical&#xD;
             antibiotics, topical treatment for Acne Vulgaris, topical anti-inflammatory agents&#xD;
             within 2 weeks prior to baseline.&#xD;
&#xD;
          -  Use for less than 3 month prior to baseline of estrogens or change in oral&#xD;
             contraceptives therapy within less than 3 month prior to baseline;&#xD;
&#xD;
          -  Use on the face of: cryodestruction or chemodestruction, dermabrasion, photodynamic&#xD;
             therapy, acne surgery, intralesional steroids or X-ray therapy within 4 weeks prior to&#xD;
             baseline..&#xD;
&#xD;
          -  Alcohol or drug abuse, according to assessment by the investigator.&#xD;
&#xD;
          -  Use of another investigational drug within 30 days prior to baseline.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Use of tanning booths, sunbathing, or excessive exposure to the sun should be&#xD;
             prohibited during the study.&#xD;
&#xD;
          -  Participation in clinical trial in the previous month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Shiri, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clalit Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eli Sprecher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avner Shemer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lev Yasmin clinic, Netanya, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lev Yasmin clinic</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky medical center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Nordau Clalit health services</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Topical</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Foam</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

